Robust Prediction of Anti-Cancer Drug Sensitivity and Sensitivity-Specific Biomarker

Heewon Park*, Teppei Shimamura¤, Satoru Miyano, Seiya Imoto

Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Abstract

The personal genomics era has attracted a large amount of attention for anti-cancer therapy by patient-specific analysis. Patient-specific analysis enables discovery of individual genomic characteristics for each patient, and thus we can effectively predict individual genetic risk of disease and perform personalized anti-cancer therapy. Although the existing methods for patient-specific analysis have successfully uncovered crucial biomarkers, their performance takes a sudden turn for the worst in the presence of outliers, since the methods are based on non-robust manners. In practice, clinical and genomic alterations datasets usually contain outliers from various sources (e.g., experiment error, coding error, etc.) and the outliers may significantly affect the result of patient-specific analysis. We propose a robust methodology for patient-specific analysis in line with the NetworkProfiler. In the proposed method, outliers in high dimensional gene expression levels and drug response datasets are simultaneously controlled by robust Mahalanobis distance in robust principal component space. Thus, we can effectively perform for predicting anti-cancer drug sensitivity and identifying sensitivity-specific biomarkers for individual patients. We observe through Monte Carlo simulations that the proposed robust method produces outstanding performances for predicting response variable in the presence of outliers. We also apply the proposed methodology to the Sanger dataset in order to uncover cancer biomarkers and predict anti-cancer drug sensitivity, and show the effectiveness of our method.

Introduction

Recently, numerous studies have attempted to personalized therapy and medicine based on advanced biomedical technologies [2,9]. A crucial issue for personal genome research is to reveal the genomic features of an individual patient that are relevant for treatment. The elastic net-type regularized regression (e.g., ridge [11], lasso [29], elastic net [34], etc.) has been widely used to uncover biomarkers, and successfully performed for identifying genomic features and predicting response variable based on high-dimensional gene expression dataset. The methods, however, can only provide results based on the average genomic features of all patients. In essence, it is not yet possible to use these methods to identify genomic features for an individual patient, thus it is hard to effective personalized treatment and medicine.

Wang et al. [30] considered the patient-specific pathway activities based on a mixed model, where the fixed effects modeled the mean pathway of gene expressions profiles for patient groups and random effects described patient variations from the group mean. Shimamura et al. [29] proposed a method, called a NetworkProfiler, for identifying patient-specific gene regulatory networks based on a varying coefficient model and kernel-based elastic net-type regularized regression. By using a Gaussian kernel function, the NetworkProfiler can effectively perform patient-specific analysis based on neighborhood samples around a patient. Although the existing elastic net-type regularization methods perform effectively for patient specific analysis, their performances take a sudden turn for the worst in the presence of outliers, because the methods are constructed by non-robust manners (e.g., least square loss function). In practice, the clinical and genomic alterations datasets usually contain outliers from various sources (e.g., experiment error, coding error, etc.), and thus the existing methods cannot effectively uncover patient-specific biomarkers and predict anti-cancer drug sensitivity.

Although the issue is critically important, relatively little attention has been paid to the robustness of patient-specific analysis. We consider a robust method to uncover patient-specific genomic features and predict anti-cancer drug response in line with the NetworkProfiler. The genomic alterations dataset is usually constructed with a large number of features for a small number of samples (i.e., high dimensional dataset), and detecting and controlling outliers in a high dimensional dataset are difficult tasks. We refer to the method for controlling outliers by using the robust Mahalanobis distance based on principal component analysis (PCA) [25]. By using the principal components, we can detect outliers in a high dimensional genomic alteration dataset based on robust Mahalanobis distance by overcoming calculation of inverse covariance matrix. Furthermore, because the principal
component space is defined by maximize the variance along each component, and outliers increase the variance of the data, we can effectively perform outlier detection [3, 23].

We propose a robust modeling strategy for patient-specific analysis, which infers patient-specific biomarkers associated with anti-cancer drug response. The proposed strategy is based on kernel-based elastic net-type regularization, and thus can perform patient-specific analysis through neighborhood samples around a target patient. Furthermore, our method can perform effectively for predicting anti-cancer drug sensitivity and identifying drug response-specific biomarkers for each patient even in the presence of outliers, since the method is based on a robust regularized regression by using a weight through the Mahalanobis distance in principal component space [25].

We conduct Monte Carlo simulations to examine the effectiveness of the proposed method, and show the outstanding performance of our method in the view point of prediction accuracy. We also apply the proposed modeling strategy to the publicly available Sanger Genome of Drug Sensitivity in Cancer dataset from the Cancer Genome Project (http://www.cancerrxgene.org/). Our methodology uncovers biomarkers for individual patients and predicts anti-cancer drug response given as IC50 values based on gene expression levels. Though Monte Carlo simulations and application to the Sanger dataset, we can see that our method performs effectively for patient-specific feature selection and prediction of interesting response variable, even in the presence of outliers.

Methods

Suppose we have \( n \) independent observations \( \{ (y_i, x_i); i = 1, \ldots, n \} \), where \( y_i \) are random response variables (e.g., anti-cancer drug response) and \( x_i \) are \( p \)-dimensional vectors of the predictor variables (e.g., genomic alterations). Consider the linear regression model,

\[
y_i = \beta_0 + x_i^T \beta + \epsilon_i, \quad i = 1, \ldots, n,
\]

where \( \beta_0 \) is an intercept, \( \beta \) is an unknown \( p \)-dimensional vector of regression coefficients and \( \epsilon_i \) are the random errors that are usually contain outliers from various sources (e.g., experiment error, coding error, etc.). It implies that the existing method would not perform well for uncovering biomarkers and predicting anti-cancer drug response, because the existing method in [5] is based on a penalized least squares loss function. It was previously shown that the elastic net-type regularization methods that are based on least square loss function perform poorly in the presence of outliers, and several robust methodologies have been proposed to identify crucial biomarkers and predict drug response. Furthermore, we can effectively perform regression modeling in the high dimensional genomic alterations dataset and in the presence of multicollinearity by imposing the penalty on the least squares loss function. Although the existing methodologies successfully identify crucial biomarkers and show remarkable performance for predicting drug response, they have been used to identify averaged biomarkers for all patients. In other words, the existing method cannot identify patient-specific characteristics in a disease.

The elastic net-type penalties enable us to simultaneously identify crucial biomarkers and predict drug response. Furthermore, we can effectively perform regression modeling in the high dimensional genomic alterations dataset and in the presence of multicollinearity by imposing the penalty on the least squares loss function. Although the existing methodologies successfully identify crucial biomarkers and show remarkable performance for predicting drug response, they have been used to identify averaged biomarkers for all patients. In other words, the existing method cannot identify patient-specific characteristics in a disease.

NetworkProfiler

Shimamura et al. [28] proposed a novel statistical method for inferring patient-specific gene regulatory networks based on a varying-coefficient structural equation model. Let \( R_1, \ldots, R_q \) be \( q \) possible regulators, and \( T_k \) be the \( k^{th} \) target gene controlled by the \( q \) regulators at \( M = m_k \) [28]. The varying coefficient structural equation model for \( T_k \) is given as

\[
T_k = \sum_{j=0}^{q} \beta_{jk}(m_j) \cdot R_j + \epsilon_k, \quad x = 1, \ldots, n,
\]

where \( \beta_{jk}(m_j) \) is a regression coefficient of \( R_j \) on \( T_k \) for the modulator \( M = m_k \). The patient-specific regression coefficients \( \beta_{jk}(m_k) \) are estimated via the kernel-based regularization method by minimizing,

\[
L(\beta_k|\epsilon_k) = \frac{1}{2} \sum_{j=1}^{q} (t_k - \beta_{jk} - \sum_{j=1}^{q} \beta_{jk} \cdot r_j)^2 K(m_j - m_k)|h_k|
+ P_{\delta_k}(\beta_{jk}),
\]

where \( \beta_{jk} = \beta_{jk}(m_k) \), and

\[
P_{\delta_k}(\beta_{jk}) = z_k \sum_{j=1}^{q} \frac{1}{2} (1 - \delta_k) \beta_{jk}^2 + \delta_k w_{jk} |\beta_{jk}|,
\]

and where \( z > 0 \) is a regularization parameter controlling model complexity. The penalty term of the elastic net is a convex combination of the ridge and lasso penalties. When \( \delta = 0 \), the elastic net becomes the ridge regression with a L2 penalty, whereas when \( \delta = 1 \), it becomes the lasso with a L1 penalty. The elastic net performs variable selection and estimation along with the properties of both lasso and ridge regression for \( 0 < \delta < 1 \).

To uncover a biomarker, the elastic net-type regularization methods (e.g., ridge, lasso, elastic net, etc.) have been widely applied, and used successfully to identify crucial genes based on the following optimization problem,

\[
L(\beta) = \arg \min_{\beta} \frac{1}{2} \sum_{i=1}^{n} (y_i - \beta_0 - \sum_{j=1}^{p} x_j \beta_j)^2 + P_{\delta}(\beta),
\]

where

\[
P_{\delta}(\beta) = z \sum_{j=1}^{p} \frac{1}{2} (1 - \delta) \beta_j^2 + \delta |\beta_j|,
\]

and where \( z > 0 \) is a regularization parameter controlling model complexity. The penalty term of the elastic net is a convex combination of the ridge and lasso penalties. When \( \delta = 0 \), the elastic net becomes the ridge regression with a L2 penalty, whereas when \( \delta = 1 \), it becomes the lasso with a L1 penalty. The elastic net performs variable selection and estimation along with the properties of both lasso and ridge regression for \( 0 < \delta < 1 \).
overcome the drawbacks of a least square loss function in regularized regression modeling [1,14,25].

We propose a robust method for patient-specific analysis in line with the NetworkProfiler.

Robust regularization for outlier-resistant patient-specific analysis

We first show how outliers could affect the estimation process when using the penalized least squares methodology. Figure 1 shows the iteration for coefficients during optimization of the regularized regression modeling with a lasso penalty [25] under the original and contaminated diabetes datasets [3] in (A) and (B), respectively. The contaminated dataset contains 10% outliers for N(5,3²) in X1 and X9 among the 10 predictor variables. The coefficients converged after 26 iterations in the original dataset, as shown in Figure 1 (A). In the presence of outliers, however, the optimization procedure with the lasso estimator is disturbed and the iteration number required for convergence is significantly increased as shown in Figure 1 (B). This implies that outliers significantly disturb the regularized regression modeling, and thus may lead to poor results in uncovering biomarkers and predicting drug response where patient-specific analysis is weak.

We propose a robust method to effectively uncover patient-specific cancer biomarkers and predict anti-cancer drug sensitivity in line with the NetworkProfiler. The genomic features dataset is constructed with a large number of features and a relatively small number of samples (i.e., high dimensional dataset), and detecting and controlling outliers in a high dimensional dataset are generally difficult tasks. To resolve the issue, we consider the weight for controlling outliers based on robust Mahalanobis distance calculated in robust principal component space, as previously demonstrated by Park and Konishi [25],

\[
R^0_{p}\ = \ \frac{\text{min}(\sqrt{k/R.M.D^0_{p}},1)}{\sum_{i=1}^{n}\text{min}(\sqrt{k/R.M.D^0_{i,p}},1)},
\]

where \(k=\chi^2(df=p^*)\) is the 95\% quantile of the \(\chi^2(df=p^*)\) distribution [14], and \(R.M.D^0_{i,p}\) is a robust Mahalanobis distance based on the robustly estimated mean \(\mathbf{1}^{p\times n}_c\) and covariance matrix \(C^{p\times p}\) by Minimum Volume Ellipsoid (MVE) calculated in the robust principal components \(Z^p\) space as follows,

\[
R.M.D^0_{i,p} = \sqrt{(z_i^p - \mathbf{1}^{p\times n}_c)(C^{p\times p}})^{-1}(z_i^p - \mathbf{1}^{p\times n}_c),
\]

where \(Z^p=([z_1^p, ..., z_n^p])^T\) is a \(p^*\)-dimensional matrix of robust principal components based on robust loadings by using the projection-pursuit technique [12]. By using the robust principal component space, we can effectively detect outliers based on the robust Mahalanobis distance, thereby overcoming the calculation of the inverse covariance matrix in a high dimensional dataset. Furthermore, the principal components space is defined by maximizing the variance along each component, and since outliers increase the variance of dataset, we are able to more faithfully detect outliers [3]. It implies that the weight \(R^0_{p}\) based on the robust Mahalanobis distance calculated in robust principal component space is a useful tool for controlling outliers in high dimensional genomic data.

We refer to the weight in (8) for outlier-resistant patient-specific analysis, and propose a robust method for uncovering biomarkers and predicting drug sensitivity for an individual patient as follows,

\[
L(\beta_i|p^*,h) = \frac{1}{2}\sum_{j=1}^{n} R^0_{p}\left(y_i - \beta_0x_i - \sum_{j=1}^{p} \beta_j x_{ij}\right)^2K(m_i - m_j|h) + P_{\delta}(\beta_i),
\]

where \(w_{ij} = 1/((\tilde{\beta}_j + \tilde{\gamma}))\) is a weight of the adaptive elastic net penalty [35].

The proposed modeling strategy is effectively conducted by using the coordinate descent algorithm based on the weighted update [6]. Our method can efficiently perform patient-specific analysis based on the Gaussian kernel function, and its effective performance can be consistently provided even in the presence of outliers by controlling outliers through the weight.

Results

We examine the effectiveness of the proposed modeling strategy as a robust method for patient-specific analysis through Monte Carlo simulations and application to cancer genomics data. To evaluate the proposed method, we compare the prediction accuracy and variable selection results of our method, the NetworkProfiler and elastic net. In our study, the NetworkProfiler is used to uncover individual biomarkers instead of gene networks. For the numerical studies, we use the adaptive elastic net penalty \(P_{\delta}(\beta_j) = \lambda \sum_{j=1}^{p} \left((1-\delta)\beta_j^2 + \delta w_{ij}\beta_j\right)[35]\) in the proposed method, NetworkProfiler and elastic net. We choose the tuning parameters \(\delta, \lambda\) and bandwidth \(h\) in Gaussian kernel function based on k-fold cross validation [18],

\[
CV(\theta) = \frac{1}{K} \sum_{v=1}^{K} \sum_{i=1}^{T_v} \left[ y_i - \sum_{j=1}^{p} x_{ij}\beta_j^{(v)}\right]^2,
\]

where \(T_v\) is the validation samples for \(v=1,2,...,K\), and the data \(T - T_v\) is used to estimate for each \(v\). In numerical studies, we use the 3-fold cross validation, which has been used in high dimensional data analysis like genomic data analysis [13,20,22,26,32]. The robust Mahalanobis distance is calculated based on the robust principal components that contributed 95\% of the total variation.

Monte Carlo simulations

We simulated 100 datasets consisting of \(n=100\) observations from the model

\[
y_i = x_i^T \beta(m_i) + \epsilon_i, \quad i=1,\ldots,n,
\]

where \(\epsilon_i\) are assumed to be distributed as \(N(0,1)\) and \(m_i\) are generated from a uniform distribution \(U[0,1]\) for \(x = 1,2,\ldots,n\). The correlation between \(x_i\) and \(x_p\) is \(p^{\rho \ast -m}\) with \(\rho = 0.5\) in \(p=1000\) dimensional multivariate normal distribution with mean zero. We consider a 1000 dimensional vector of coefficients with randomly selected 100 non-zero and 900 zero coefficients.

Two types of coefficient functions in the above varying coefficient model are considered, as shown in Figure 2. We consider \(\%\) of samples as outliers in \(n=100\) samples. If the \(i^{th}\)
sample is an outliers, \( q_i \sim N(5, \sigma^2) \) and 1\% of \( x_{ij} (j = 1, \ldots, p) \) follow \( N(5, \sigma^2) \). Here we set \( s = 5, 10, 15, \) and 20, and \( \sigma^2 = 1 \) and \( \sigma^2 = 5 \) in simulations 1 and 2, respectively.

We consider a training dataset with 75 samples and a test dataset with 25 samples in each 100 simulations. The hyperparameters are selected by 3-fold cross validation in the training dataset, and the prediction errors are calculated in test dataset based on the selected parameters. We then compare the prediction accuracy given as average of the median squared error, and the variable selection accuracy given as true positive (i.e., average percentage of non-zero coefficients, that were estimated as non-zero) and true negative (i.e., the average percentage of true zero coefficients, that were correctly set to zero) for each of the 100 generated datasets.

A large number of predictor variables leads to time consuming analysis, and thus increases the overall computational cost of a method. Furthermore, it has been exposed that a large number of predictor variables with noisy genes may disturb the modeling procedure, and thus leads to poor prediction results [19]. Table 1 shows the prediction accuracy of the NetworkProfiler based on all features and based on a pre-selected small number of features that have the highest variance. It can be seen through Table 1 that

![Figure 1. Iteration for coefficients in the regularized regression modeling with lasso (i.e., \( \phi = 1 \)) penalty.](doi:10.1371/journal.pone.0108990.g001)

![Figure 2. Coefficient functions of varying coefficient model.](doi:10.1371/journal.pone.0108990.g002)
**Table 1.** Comparison prediction accuracy of model with $p = 1000$ and $p = 200$.

|       | 5%   | 10%  | 15%  | 20%  |
|-------|------|------|------|------|
|       | $p=1000$ |      |      |      |
|       | $p=200$  |      |      |      |
|       | $N=(5, 5)$ | $N=(5, 1)$ | $N=(5, 5)$ | $N=(5, 1)$ |
| 5%    | 0.259 | 0.333 | 0.266 | 0.254 |
| 10%   | 0.280 | 0.290 | 0.266 | 0.290 |
| 15%   | 0.259 | 0.289 | 0.251 | 0.274 |
| 20%   | 0.251 | 0.274 | 0.254 | 0.254 |

**Table 2.** Results of simulation 1 with Outlier for $N(5, 1)$.

|       | Type 1 |      |      |      | Type 2 |      |      |      |
|-------|--------|------|------|------|--------|------|------|------|
|       |        | T.P  | T.N  | P.E  |        | T.P  | T.N  | P.E  |
|       |        |      |      |      |        |      |      |      |
| 5%    | ELA    | -    | -    | 0.338|        | -    | -    | 0.324|
|       | NP     | 0.71 | 1.00 | 0.290| 0.70   | 1.00 | 0.276|
|       | R      | 0.71 | 1.00 | 0.285| 0.70   | 1.00 | 0.310|
| 10%   | ELA    | -    | -    | 0.325|        | -    | -    | 0.329|
|       | NP     | 0.69 | 1.00 | 0.290| 0.70   | 1.00 | 0.303|
|       | R      | 0.69 | 1.00 | 0.284| 0.70   | 1.00 | 0.294|
| 15%   | ELA    | -    | -    | 0.289|        | -    | -    | 0.264|
|       | NP     | 0.71 | 1.00 | 0.288| 0.70   | 1.00 | 0.258|
|       | R      | 0.71 | 1.00 | 0.287| 0.70   | 1.00 | 0.259|
| 20%   | ELA    | -    | -    | 0.285|        | -    | -    | 0.255|
|       | NP     | 0.71 | 1.00 | 0.254| 0.69   | 1.00 | 0.258|
|       | R      | 0.71 | 1.00 | 0.244| 0.69   | 1.00 | 0.255|

doi:10.1371/journal.pone.0108990.t001
doi:10.1371/journal.pone.0108990.t002
consideration of all features does not produce high prediction performance compared with the performance of a regression model built on a pre-selected small number of features. It implies that there is no need to consider all features for patient-specific analysis, because it leads to inefficient modeling without improving model performance.

Thus, we compare the proposed robust method to the NetworkProfiler and elastic net based on model with $p = 200$ predictor variables that have the highest variance in all samples. Tables 2 and 3 show the simulation results (i.e., true positive (T.P), true negative (T.N) and prediction error (P.E)) in simulations 1 and 2, respectively, where the bold values indicate the best performance among the three methods (i.e., elastic net: ELA, NetworkProfiler: NP, robust method: R). The varying coefficient model produces discriminative variable selection results in each sample, and thus we only compare the feature selection results of the NetworkProfiler and proposed robust one, because the elastic net cannot perform sample-specific feature selection.

Tables 2 and 3 show that the proposed robust method for patient-specific analysis outperforms for predicting response variable in all simulation situations and coefficient function types. We also observe that the proposed robust method and NetworkProfiler make no difference results in variable selection. From the results, we can see that controlling outliers in the modeling procedure produces outlier-resistant estimation results, and the results lead to outstanding prediction of interesting response variable.

Real world example: Sanger dataset

We apply the proposed modeling strategy to the publicly available Sanger Genomics of Drug Sensitivity in Cancer dataset from the Cancer Genome Project (http://www.cancerrxgene.org/). The main goal of the project is to identify the molecular features of various cancers and to predict sensitivity of anti-cancer drugs. The dataset consists of gene expression levels, copy number and mutation status for 654 cell lines. The IC50 values (i.e., half maximal inhibitory drug concentrations) of 138 drugs are given as the natural log of drug sensitivity value. The IC50 values from the Sanger dataset contain not a few of missing values, and thus we perform biomarkers discovery and anti-cancer drug response prediction based on 200 randomly selected samples, of which 150 cell lines were used as a training data and 50 cell lines were used as a test data for each of the 138 drugs.

To evaluate the proposed robust methodology, we first decide whether the dataset constructed with IC50 values of each drug and expression levels of 13,321 genes is contaminated or not. For each of the 138 dataset (i.e., gene expression levels and IC50 values) corresponding 138 drugs, we find a first principal component of the dataset, and then decide based on the following criterion,

$$C_{dr} = \frac{1}{n} \sum_{i=1}^{n} \min \left( \frac{(\sqrt{\text{MD}_{p}^{i}} - 1)}{R_{MD_{p}^{i}}}, 1 \right), \quad dr = 1, ..., 138, \quad (14)$$

where $R_{MD_{p}^{i}}$ is the robust Mahalanobis distance calculated from the first principal component. The criterion $C_{dr}$ has a zero value in a non-contaminated dataset, while a large value of $C_{dr}$ indicates that the dataset contains outliers. Figure 3 shows the sorted $C_{dr}$ values for the 138 datasets.

We consider the datasets with $C_{dr}$ located in top-right side of Figure 3 as contaminated datasets, which have relatively large $C_{dr}$ values that are highly deviated from the mean of $C_{dr}$ values. The proposed robust method is then applied to the contaminated...
datasets to evaluate the performance of the methods when identifying biomarkers and predicting anti-cancer drug sensitivity. We compare the prediction accuracy based on 10 datasets corresponding to the 10 drugs shown as red dots in Figure 3: drugs FTI.277, DMOG, NSC.87877, AKT.inhibitor.VIII, Midostaurin, BMS.754807, Thapsigargin, Bleomycin, Doxorubicin, Epothilone.B.

As mentioned previously, a large number of features not only leads to inefficient modeling, but may also produce poor results compared with modeling based on a pre-selected small number of features. We first compare the prediction accuracy (i.e., median squared error of 50 test samples) of anti-cancer drug response based on expression levels of 133 (1% of total 13,321 genes) genes and the 500 genes that have the highest variance based on the NetworkProfiler in Table 4. Table 4 shows that modeling based on the expression levels of 133 genes produces outstanding prediction accuracy compared with modeling based on 500 genes. From the result, we can also conclude that there is no need to consider a large number of genes with noise, and that a large number of features only leads to inefficient modeling and poor prediction results. Thus, we evaluate the proposed robust method compared with the NetworkProfiler and elastic net based on the expression levels of 133 genes. Table 5 shows the median squared error of 50 test samples as a prediction error of anti-cancer drug response. The proposed robust method outperforms the existing methods for predicting anti-cancer drug response in the contaminated datasets.

Figure 4 shows the uncovered cancer biomarkers that are selected in greater than 80% of models for each 150 tissues (i.e., selected in greater than 120 samples based on varying coefficient model) by our method for each drug’s response. In order to show a reliability of our method, we also show the 10 most frequently discovered genes when predicting the sensitivity of 10 drugs and their references in Table 6. There are differences between the biomarkers discovered based on our method and those discovered using the elastic net [8], since our method identifies cancer biomarkers for each patient rather than the average biomarkers for all samples. However, the drug sensitivity-specific biomarkers discovered by our method were strongly supported as true cancer biomarkers in the literatures (column of “Reference” in Table 6). The result implies that the proposed method for patient-specific analysis produces a reliable result for uncovering cancer biomarkers.

In short, our method is a useful tool for predicting anti-cancer drug sensitivity and uncovering patient-specific cancer biomarkers.

Table 4. Prediction results of drug sensitivity by using NetworkProfiler based on 133 and 500 genes.

| Drug            | FTI.277 | DMOG | NSC.87877 | AKT.inhibitor.VIII | Midostaurin |
|-----------------|---------|------|-----------|-------------------|-------------|
| p500            | 0.402   | 0.222| 0.208     | 0.303             | 0.263       |
| p133            | 0.291   | 0.239| 0.211     | 0.232             | 0.134       |

| Drug            | BMS.754807 | Thapsigargin | Bleomycin | Doxorubicin | Epothilone.B |
|-----------------|------------|--------------|-----------|-------------|--------------|
| p500            | 0.107      | 0.140        | 0.201     | 0.318       | 0.760        |
| p133            | 0.124      | 0.131        | 0.049     | 0.182       | 0.725        |

doi:10.1371/journal.pone.0108990.t004
Discussion

We have proposed a novel outlier-resistant method for uncovering patient-specific biomarkers and predicting anti-cancer drug response. By using the robust Mahalanobis distance calculated in robust principal component space, the proposed method effectively detects and controls outliers in high dimensional genomic alterations datasets. Thus, the proposed robust method can effectively perform to uncover cancer biomarkers and predict drug sensitivity, even in the presence of outliers. From the Monte Carlo simulations, we have found that our method shows outstanding prediction accuracy as compared to the existing NetworkProfiler and elastic net. We have also applied the proposed method to the Sanger dataset from the Cancer Genome Project. By using our method, we have uncovered cancer biomarkers and predicted anti-cancer drug response. It can be seen from the results that the proposed method is a useful tool for predicting anti-cancer drug response. Furthermore, the biomarkers uncovered by our method had been previously identified as cancer biomarkers. The results implies that our method provides not only reliable feature selection, but also accurate prediction results.

There is currently much discussion about patient-specific analysis and personalized medicine based on high dimensional genomic datasets. We expect that our methodology will be useful for the fields, since genomic data usually contains outliers. Although the patient-specific method based on a varying coefficient model is an efficient tool, it controls the effects of observations in order to provide sample-specific results. In other words, it reduces the effect of observations far from a target patient, and thus leads to a high dimensional data frame. Building models based on a large number of features with a small number of samples can lead to overfitting in feature selection, and can

| Table 5. Comparison of prediction accuracy of drug sensitivity. |
|---------------------------------------------------------------|
|                  | FTI.277 | DMOG  | NSC.87877 | AKT.inhibitor.VIII | Midostaurin |
| R                | 0.293   | 0.220 | 0.162     | 0.177            | 0.120       |
| NP               | 0.291   | 0.239 | 0.211     | 0.232            | 0.134       |
| Elastic net      | 0.269   | 0.561 | 0.323     | 0.447            | 0.477       |
|                  | BMS.754807 | Thapsigargin | Bleomycin | Doxorubicin | Epothilone.B |
| R                | 0.099   | 0.120 | 0.044     | 0.153            | 0.621       |
| NP               | 0.124   | 0.131 | 0.049     | 0.182            | 0.725       |
| Elastic net      | 0.720   | 0.274 | 0.279     | 0.367            | 0.954       |

Figure 4. Identified biomarkers on each anti-cancer drug.
doi:10.1371/journal.pone.0108990.g004
produce inefficient prediction results. In order to improve modeling performance, future work can involve extending the patient-specific analysis based on the bootstrap technique.

The Sanger dataset from the Cancer Genome Project provides comprehensive information about the molecular features of a cancer (e.g., mutation, expression levels and copy number variation) and response of various anti-cancer drugs. Thus, analysis of the dataset may provide informative results about the systems biology of cancer and valuable information for personalized treatment and anti-cancer therapy. The IC50 values of 138 drugs given as drug sensitivity, however, contain many missing values (from 44 to 364 missing values in total 654 cell lines). In order to effectively use the Sanger dataset to reveal the mechanism of cancer, rather than ignoring the incomplete fields, a proper treatment of the missing values is required.

Furthermore, we have also identified through numerical studies that a large number of noisy features may disturb modeling performance, and thus strategies for pre-selecting a candidate set will be required to improve modeling performance.

Acknowledgments
This research used computational resources of the K computer provided by the RIKEN Advanced Institute for Computational Science through the HPCI System Research project (Project ID:h10230) and the Super Computer System, Human Genome Center, Institute of Medical Science, University of Tokyo. The authors would like to thank the associate editor and anonymous reviewers for the constructive and valuable comments that improved the quality of the paper.

Author Contributions
Conceived and designed the experiments: HP. Contributed reagents/materials/analysis tools: HP TS SI SM. Wrote the paper: HP SI.

Table 6. Identified biomarkers shown the top 10 highest frequency.

| Gene      | Freq | Reference | Disease                                      |
|-----------|------|-----------|----------------------------------------------|
| FN1       | 1,019| [10,24]   | breast cancer, colorectal cancer              |
| TACSTD2   | 962  | [21,31]   | breast cancer                                |
| IGFBP1    | 960  | [15,27]   | metastatic caners, Germ Cell Tumors          |
| IGFBP4    | 957  | [12]      | leukocytes in human peripheral blood, breast cancer |
| IGL1      | 939  | [15]      | Germ Cell Tumors                             |
| COL1A2    | 935  | [17,21]   | breast cancer, prostate cancer                |
| SERPINE2  | 935  | [7]       | chronic obstructive pulmonary disease         |
| CD24      | 855  | [16,33]   | Breast Cancer                                |
| IFITM3    | 855  | [4,21]    | breast cancer, Colon Cancer                   |
| LDHB      | 833  | [23]      | Breast Cancer                                |

doi:10.1371/journal.pone.0108990.t006

References
1. Alfons A, Croux C, Gelper S (2013) Sparse least trimmed squares regression for analyzing high-dimensional large data sets. Ann Appl Stat 7: 226-249.
2. Chin L, Andersen JM, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nature Medicine 17: 297-303.
3. Elfen B, Hasted T, Johnstone I, Tibshirani R (2004) Least angle regression. Ann Stat 32: 407-499.
4. Fan J, Peng Z, Zhou C, Qin G, Tang H, et al. (2008) Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of FFIT3 as a biomarker of early colon carcinogenesis. Cancer 115: 666-75.
5. Filzmoser P, Maronna R, Werner M (2008) Outlier identification in high dimensions. Comput Stat Data Anal 52: 1694-1711.
6. Friedman J, Hastie T, Tibshirani R (2010) Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Sotw 33: 1-22.
7. Fumimoto K, Ikeda S, Arai T, Tanaka N, Kumasaka T, et al. (2010) Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases. BMC Med Genet 11: 159.
8. Garnett MJ, Edelman EJ, Heidorn ES, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
9. Guo S, Yush G, Lee JJ (2013) Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemp Clin Trials 36: 642-650.
10. Hellemann J, Jansen MPHM, Ruigrok-Ritstier K, van Staveren I, Look MP, et al. (2008) Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 19(23).
11. Hoerl AE, Kennard RW (1970) Ridge regression: biased estimation for nonorthogonal problems. Techonometrics 12(1): 55-67.
12. Hubert M, Rousseuw PJ, Vanderven Branden K. (2005) ROBPCA: a new approach to robust principal components analysis. Technometrics 47: 64-79.
13. Jacob L, Obozinski G, Vert JP (2009) Graph lasso and overlap group lasso. Proc 26th Ann Inter Conf Mach learn 433-440.
14. Khan JA, Van Arsd S, Zamar RH (2007) Robust linear model selection based on least angle regression. J Am Stat Assoc 102: 1289-1299.
15. Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin LX, et al. (2009) Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. J Clin Oncol 27(31): 5240-5247.
16. Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluss K, et al. (2003) CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9: 4906-4913.
17. Lapointe J, Li C, Higgins JP, Rijn van de M, Bair E, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Nat Acad Sci U.S.A. 101(5): 811-816.
18. Lan X, Annie Q (2012). Variable Selection in High-dimensional Varying-coefficient Models with Global Optimality. J Mach Learn Res 13: 1973-1990.
19. Li X, Mo L, Yuan X, Zhang J (2014) Linearized alternating direction method of multipliers for sparse group and fused LASSO models. Comput Stat Data Anal 79: 203-221.
20. Li X, Mo L, Yuan X, Zhang J (2014) Linearized alternating direction method of multipliers for sparse group and fused LASSO models. Comput Stat Data Anal 79: 203-221.
21. Loss LA, Salandnam A, Durink S, Nauitya S, Flaecher D, et al. (2010) Prediction of epigenetically regulated genes in breast cancer cell lines. BMC Bioinformatics 11:305.
22. Ma S, Song X, Huang J (2007) Supervised group lasso with applications to microarray data analysis. BMC Bioinformatics 8(60).
23. Mark IM, Adam SA, Yonglei S, Thomas H, Tom T, et al. (2012) An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res 72: 5812-5823.
24. Mech PF, Farrell CL, Crotchov R, Crimm H, Miller SK, et al. (2009) A Gene Expression Classifier of Node-Positive Colorectal Cancer. Neoplasia 11: 1074-1083.
25. Park H, Konishi S (2014) Robust solution path for high dimensional sparse regression modeling. Commun Stat Simul Comput, In press.
26. Peralta B, Soto A (2014) Embedded local feature selection within mixture of experts. Inf. Sci. 269: 176–187.
27. Robert NJ, Peter G, Michael C, Saurabh P, Lara L, et al. (2009) Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res 15(24): 7642–7651.
28. Shimamura T, Imoto S, Shimada Y, Hosono Y, Nuida A, et al. (2011) A novel network profiling analysis reveals system changes in epithelial-mesenchymal transition. PLoS ONE 6(5): e19004.
29. Tibshirani R (1996) Regression shrinkage and selection via the lasso. J R Stat Soc Series B 28: 267–288.
30. Wang L, Chen X, Zhang B (2012) Statistical analysis of patient-specific pathway activities via mixed models. J Biom Biostat 8(1): 7313.
31. Wu M, Liu L, Chan C (2011) Identification of novel targets for breast cancer by exploring gene switches on a genome scale. BMC Genomics 12(547).
32. Yamada M, Jitkrittum W, Sigal I, Xing EP, Sugiyama M (2014) High-dimensional feature selection by feature-wise kernelized lasso. Neur Comput 26(1): 185–207.
33. Yin H, Glass J (2011) The phenotypic radiation resistance of CD44+/CD24− cells breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS ONE 6(9): e24600.
34. Zou H, Hastie T (2002) Regularization and variable selection via the elastic net. J R Stat Soc. Series B 67: 301–320.
35. Zou H, Zhang HH (2009) On the adaptive elastic-net with a diverging number of parameters. Ann Stat 37(4): 1733–1751.